Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens

References

• Ramon G. Sur la toxine et surranatoxine diphtheriques. Ann. Inst. Pasteur38, 1–7 (1924).
   Google Scholar
• Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. In: Vaccine Design: The Subunit and Adjuvant Approach. Powell MF, Newman MJ (Eds). Plenum Press, NY, USA, 141–228 (1995).
   Google Scholar
• Edelman R. Adjuvants for the future. In: New Generation Vaccines. Levine MM, Woodrow GC, Kaper JB, Cobon GS (Eds). Marcel Dekker Inc., NY, USA, 173–192 (1997).
   Google Scholar
• Lindblad EB. Aluminium compounds for use in vaccines. Immunol. Cell Biol.82(5), 497–505 (2004).
   PubMed Web of Science ®Google Scholar
• Lindblad EB. Aluminium adjuvant – in retrospect and prospect. Vaccine22(27–28), 3658–3668 (2004).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev. Vaccines6(5), 699–710 (2007).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Nicholson KG, Hoschler K et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N. Engl. J. Med.359(15), 1631–1633 (2008).
   PubMed Web of Science ®Google Scholar
• Petaja T, Keranen H, Karppa T et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10–18 years. J. Adolesc. Health44(1), 33–40 (2009).
   PubMed Web of Science ®Google Scholar
• Baldridge JR, Crane RT. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods19(1), 103–107 (1999).
   PubMed Web of Science ®Google Scholar
• Dagan R, Amir J, Livni G et al. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Pediatr. Infect. Dis. J.26(9), 787–793 (2007).
   PubMed Web of Science ®Google Scholar
• Patel GB, Sprott GD. Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems. Crit. Rev. Biotechnol.19(4), 317–357 (1999).
   PubMed Web of Science ®Google Scholar
• Krishnan L, Dennis Sprott G. Archaeosomes as self-adjuvanting delivery systems for cancer vaccines. J. Drug Target.11(8–10), 515–524 (2003).
   PubMed Web of Science ®Google Scholar
• Krishnan L, Dicaire CJ, Patel GB, Sprott GD. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum. Infect. Immun.68(1), 54–63 (2000).
   PubMed Web of Science ®Google Scholar
• Mishra N, Goyal AK, Tiwari S et al. Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers. Expert Opin. Ther. Pat.20(5), 661–679 (2010).
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr. Opin Immunol.21(1), 23–29 (2009).
   PubMed Web of Science ®Google Scholar
• McKee AS, Munks MW, Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity27(5), 687–690 (2007).
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev.156, 199–209 (1997).
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol.54, 1–13 (1989).
   PubMedGoogle Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity [see comments]. Nature388(6640), 394–397 (1997).
   PubMed Web of Science ®Google Scholar
• Fearon DT. Seeking wisdom in innate immunity. Nature388(6640), 323–324 (1997).
   PubMed Web of Science ®Google Scholar
• Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science272(5258), 50–53 (1996).
   PubMed Web of Science ®Google Scholar
• Yip HC, Karulin AY, Tary-Lehmann M et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol.162(7), 3942–3949 (1999).
   PubMed Web of Science ®Google Scholar
• Ribi E, Amano K, Cantrell JL, Schwartzman S, Parker R, Takayama K. Preparation and antitumor activity of nontoxic lipid A. Cancer Immunol. Immunother.12, 91–96 (1982).
   Web of Science ®Google Scholar
• Qureshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained form the lipopolysaccharide of Salmonella typhimurium. J. Biol. Chem.257(19), 11808–11815 (1982).
   PubMed Web of Science ®Google Scholar
• Baker PJ, Haslov KR, Fauntleroy MB, Stashak PW, Myers K, Ulrich JT. Enrichment of suppressor T cells by means of binding to monophosphoryl lipid A. Infect. Immun.58(3), 726–731 (1990).
   PubMed Web of Science ®Google Scholar
• Brunner R, Wallmann J, Szalai K et al. The impact of aluminium in acid-suppressing drugs on the immune response of BALB/c mice. Clin. Exp. Allergy37(10), 1566–1573 (2007).
   PubMed Web of Science ®Google Scholar
• Domer JE, Human LG, Andersen GB, Rudbach JA, Asherson GL. Abrogation of suppression of delayed hypersensitivity induced by Candida albicans-derived mannan by treatment with monophosphoryl lipid A. Infect. Immun.61(5), 2122–2130 (1993).
   PubMed Web of Science ®Google Scholar
• Gustafson GL, Rhodes MJ. Bacterial cell wall products as adjuvants: early interferon γ as a marker for adjuvants that enhance protective immunity. Res. Immunol.143(5), 483–488 (1992).
   PubMedGoogle Scholar
• Schneerson R, Fattom A, Szu SC et al. Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL. J. Immunol.147(7), 2136–2140 (1991).
   PubMed Web of Science ®Google Scholar
• Garg M, Subbarao B. Immune responses of systemic and mucosal lymphoid organs to Pnu-Imune vaccine as a function of age and the efficacy of monophosphoryl lipid A as an adjuvant. Infect. Immun.60(6), 2329–2336 (1992).
   PubMed Web of Science ®Google Scholar
• Ambrosch F, Wiedermann G, Kundi M et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine18(20), 2095–2101 (2000).
   PubMed Web of Science ®Google Scholar
• Fries LF, Gordon DM, Richards RL et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl Acad. Sci. USA89(1), 358–362 (1992).
   PubMed Web of Science ®Google Scholar
• Keefer MC, Graham BS, McElrath MJ et al. Safety and immunogenicity of Env 2–3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses12(8), 683–693 (1996).
   PubMed Web of Science ®Google Scholar
• Le TP, Church LW, Corradin G et al. Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants. Vaccine16(2–3), 305–312 (1998).
   PubMed Web of Science ®Google Scholar
• Schultz N, Oratz R, Chen D, Zeleniuch-Jacquotte A, Abeles G, Bystryn JC. Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine13(5), 503–508 (1995).
   PubMed Web of Science ®Google Scholar
• Mitchell AD, Myhr BC, Rudd CJ, Caspary WJ, Dunkel VC. Evaluation of the L5178Y mouse lymphoma cell mutagenesis assay: methods used and chemicals evaluated. Environ. Mol. Mutagen.12(Suppl. 13), 1–18 (1988).
   PubMedGoogle Scholar
• Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res.48(20), 5883–5893 (1988).
   PubMed Web of Science ®Google Scholar
• MacLean GD, Bowen-Yacyshyn MB, Samuel J et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen–Friedenreich) determinant using a synthetic carbohydrate antigen. J. Immunother.11(4), 292–305 (1992).
   PubMed Web of Science ®Google Scholar
• MacLean GD, Reddish M, Koganty RR et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol. Immunother.36(4), 215–222 (1993).
   PubMed Web of Science ®Google Scholar
• Rickman LS, Gordon DM, Wistar R Jr et al. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet337(8748), 998–1001 (1991).
   PubMed Web of Science ®Google Scholar
• Gordon DM, McGovern TW, Krzych U et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein–hepatitis B surface antigen subunit vaccine. J. Infect. Dis.171(6), 1576–1585 (1995).
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy56(6), 498–505 (2001).
   PubMed Web of Science ®Google Scholar
• Patel P, Salapatek AM. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev. Vaccines5(5), 617–629 (2006).
   PubMed Web of Science ®Google Scholar
• Bahr GM, Darcissac E, Bevec D, Dukor P, Chedid L. Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide. Int. J. Immunopharmacol.17(2), 117–131 (1995).
   PubMed Web of Science ®Google Scholar
• Palache AM, Beyer WE, Hendriksen E et al. Adjuvancy and reactogenicity of N-acetylglucosaminyl-N-acetylmuramyl-dipeptide (GMDP) orally administered just prior to trivalent influenza subunit vaccine. A double-blind placebo-controlled study in nursing home residents. Vaccine14(14), 1327–1330 (1996).
   PubMed Web of Science ®Google Scholar
• Hart MK, Palker TJ, Matthews TJ et al. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J. Immunol.145(8), 2677–2685 (1990).
   PubMed Web of Science ®Google Scholar
• Ivins BE, Welkos SL, Little SF, Crumrine MH, Nelson GO. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immun.60(2), 662–668 (1992).
   PubMed Web of Science ®Google Scholar
• Kahn JO, Sinangil F, Baenziger J et al. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis.170(5), 1288–1291 (1994).
   PubMed Web of Science ®Google Scholar
• Namba K, Nakajima R, Otani T, Azuma I. Oral application of romurtide, a synthetic muramyl dipeptide derivative, stimulates nonspecific resistance to microbial infections and hematopoiesis in mice. Vaccine14(12), 1149–1153 (1996).
   PubMed Web of Science ®Google Scholar
• Namba K, Nitanai H, Otani T, Azuma I. Romurtide, a synthetic muramyl dipeptide derivative, accelerates peripheral platelet recovery in nonhuman primate chemotherapy model. Vaccine14(14), 1322–1326 (1996).
   PubMed Web of Science ®Google Scholar
• Kaji M, Kaji Y, Kaji M et al. Phase 1 clinical tests of influenza MDP-virosome vaccine (KD-5382). Vaccine10(10), 663–667 (1992).
   PubMed Web of Science ®Google Scholar
• van den Akker F, Sarfaty S, Twiddy EM, Connell TD, Holmes RK, Hol WG. Crystal structure of a new heat-labile enterotoxin, LT-IIb. Structure4(6), 665–678 (1996).
   PubMed Web of Science ®Google Scholar
• Vajdy M, Singh M, Ugozzoli M et al. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology110(1), 86–94 (2003).
   PubMed Web of Science ®Google Scholar
• Spangler BD. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev.56(4), 622–647 (1992).
   PubMedGoogle Scholar
• Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun.63(5), 1617–1623 (1995).
   PubMed Web of Science ®Google Scholar
• Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun.65(7), 2821–2828 (1997).
   PubMed Web of Science ®Google Scholar
• Douce G, Giannelli V, Pizza M et al. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Infect. Immun.67(9), 4400–4406 (1999).
   PubMed Web of Science ®Google Scholar
• Di Tommaso A, Saletti G, Pizza M et al. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun.64(3), 974–979 (1996).
   PubMed Web of Science ®Google Scholar
• Giannelli V, Fontana MR, Giuliani MM, Guangcai D, Rappuoli R, Pizza M. Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop. Infect. Immun.65(1), 331–334 (1997).
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Del Giudice G, Giannelli V et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med.187, 1123–1132 (1998).
   PubMed Web of Science ®Google Scholar
• Barchfeld GL, Hessler AL, Chen M, Pizza M, Rappuoli R, Van Nest GA. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Vaccine17(7–8), 695–704 (1999).
   PubMed Web of Science ®Google Scholar
• Vajdy M, Singh M, Kazzaz J et al. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res. Hum. Retroviruses20(11), 1269–1281 (2004).
   PubMed Web of Science ®Google Scholar
• Srivastava IK, Stamatatos L, Kan E et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J. Virol.77(20), 11244–11259 (2003).
   PubMed Web of Science ®Google Scholar
• Zhou F, Goodsell A, Uematsu Y, Vajdy M. Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant. Clin. Vaccine Immunol.16(4), 471–478 (2009).
   PubMedGoogle Scholar
• Vajdy M, Baudner B, Del Giudice G, O’Hagan D. A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza. Clin. Immunol.123(2), 166–175 (2007).
   PubMed Web of Science ®Google Scholar
• Goodsell A, Zhou F, Gupta S et al. β7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery. Immunology123(3), 378–389 (2008).
   PubMed Web of Science ®Google Scholar
• Bogers WM, Davis D, Baak I et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology382(2), 217–225 (2008).
   PubMed Web of Science ®Google Scholar
• Barnett SW, Srivastava IK, Kan E et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS22(3), 339–348 (2008).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. Nature391(6670), 851 (1998).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med.6(12), 1403–1406 (2000).
   PubMed Web of Science ®Google Scholar
• Barackman JD, Ott G, Pine S, O’Hagan DT. Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization. Clin. Diagn. Lab. Immunol.8(3), 652–657 (2001).
   PubMedGoogle Scholar
• Ryan EJ, McNeela E, Murphy GA et al. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun.67(12), 6270–6280 (1999).
   PubMed Web of Science ®Google Scholar
• Jakobsen H, Schulz D, Pizza M, Rappuoli R, Jonsdottir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect. Immun.67(11), 5892–5897 (1999).
   PubMed Web of Science ®Google Scholar
• Kazzaz J, Neidleman J, Singh M, Ott G, O’Hagan DT. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Control Release67(2–3), 347–356 (2000).
   PubMed Web of Science ®Google Scholar
• Colwell WM, Simmons DG, Harris JR, Fulp TG, Carrozza JH, Maag TA. Influence of some physical factors on survival of Marek’s disease vaccine virus. Avian Dis.19(4), 781–790 (1975).
   PubMed Web of Science ®Google Scholar
• Singh M, Vajdy M, Gardner J, Briones M, O’Hagan D. Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine20(3–4), 594–602 (2001).
   PubMed Web of Science ®Google Scholar
• Messina JP, Gilkeson GS, Pisetsky DS. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol.147(6), 1759–1764 (1991).
   PubMed Web of Science ®Google Scholar
• Tokunaga T, Yamamoto H, Shimada S et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl Cancer Inst.72(4), 955–962 (1984).
   PubMed Web of Science ®Google Scholar
• Krieg AM, Stein CA. Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res. Dev.5(4), 241 (1995).
   PubMedGoogle Scholar
• Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature374(6522), 546–549 (1995).
   PubMed Web of Science ®Google Scholar
• Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12, and IFNγ. Proc. Natl Acad. Sci. USA93(7), 2879–2883 (1996).
   PubMed Web of Science ®Google Scholar
• Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial-DNA induces murine interferon-γ production by stimulation of interleukin-12 and tumor-necrosis-factor-α. Cell. Immunol.167(1), 72–78 (1996).
   PubMed Web of Science ®Google Scholar
• Yi AK, Chace JH, Cowdery JS, Krieg AM. IFN-γ promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J. Immunol.156(2), 558–564 (1996).
   PubMed Web of Science ®Google Scholar
• Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science298(5601), 2199–2202 (2002).
   PubMed Web of Science ®Google Scholar
• Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature406(6797), 782–787 (2000).
   PubMed Web of Science ®Google Scholar
• Thomas LJ, Hammond RA, Forsberg EM et al. Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice. Hum. Vaccin.5(2), 79–84 (2009).
   PubMed Web of Science ®Google Scholar
• Malaspina A, Moir S, DiPoto AC et al. CpG oligonucleotides enhance proliferative and effector responses of B cells in HIV-infected individuals. J. Immunol.181(2), 1199–1206 (2008).
   PubMed Web of Science ®Google Scholar
• Jurk M, Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs21(6), 387–401 (2007).
   PubMed Web of Science ®Google Scholar
• Takeshita F, Leifer CA, Gursel I et al. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol.167(7), 3555–3558 (2001).
   PubMed Web of Science ®Google Scholar
• Bauer M, Redecke V, Ellwart JW et al. Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J. Immunol.166(8), 5000–5007 (2001).
   PubMed Web of Science ®Google Scholar
• Cazeaux N, Bennasser Y, Vidal PL, Li Z, Paulin D, Bahraoui E. Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter. Vaccine20(27–28), 3322–3331 (2002).
   PubMed Web of Science ®Google Scholar
• Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol.158(8), 3635–3639 (1997).
   PubMed Web of Science ®Google Scholar
• Krieg AM, Davis HL. Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther.3(1), 15–24 (2001).
   PubMedGoogle Scholar
• Barnett SW, Lu S, Srivastava I et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol.75(12), 5526–5540 (2001).
   PubMed Web of Science ®Google Scholar
• Klinman DM. Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev.8(2), 181–184 (1998).
   PubMedGoogle Scholar
• Krieg AM, Love-Homan L, Yi AK, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol.161(5), 2428–2434 (1998).
   PubMed Web of Science ®Google Scholar
• Moldoveanu Z, Clements ML, Prince SJ, Murphy BR, Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine13(11), 1006–1012 (1995).
   PubMed Web of Science ®Google Scholar
• Kovarik J, Bozzotti P, Love-Homan L et al. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J. Immunol.162(3), 1611–1617 (1999).
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol.161(9), 4463–4466 (1998).
   PubMed Web of Science ®Google Scholar
• Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl Acad. Sci. USA95(26), 15553–15558 (1998).
   PubMed Web of Science ®Google Scholar
• Eastcott JW, Holmberg CJ, Dewhirst FE, Esch TR, Smith DJ, Taubman MA. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine19(13–14), 1636–1642 (2001).
   PubMed Web of Science ®Google Scholar
• Horner AA, Ronaghy A, Cheng PM et al. Immunostimulatory DNA is a potent mucosal adjuvant. Cell. Immunol.190(1), 77–82 (1998).
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Davis HL. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine19(4–5), 413–422 (2000).
   PubMed Web of Science ®Google Scholar
• Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine17(1), 19–25 (1999).
   PubMed Web of Science ®Google Scholar
• Broide D, Schwarze J, Tighe H et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J. Immunol.161(12), 7054–7062 (1998).
   PubMed Web of Science ®Google Scholar
• Burke B, Gomez-Roman VR, Lian Y et al. Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits. Virology387(1), 147–156 (2009).
   PubMed Web of Science ®Google Scholar
• Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol.146(2), 431–437 (1991).
   PubMed Web of Science ®Google Scholar
• Glaueri AM, Dingle JT, Lucy JA. Action of saponins on biological membranes. Nature196, 953 (1962).
   Google Scholar
• Powell MF, Cleland JL, Eastman DJ et al. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons [published erratum appears in AIDS Res. Hum. Retroviruses 1995 May; 11(5), 661]. AIDS Res. Hum. Retroviruses10(Suppl. 2), S105–S108 (1994).
   Web of Science ®Google Scholar
• Kensil CR, Barrett C, Kushner N et al. Development of a genetically engineered vaccine against feline leukemia virus infection. J. Am. Vet. Med. Assoc.199(10), 1423–1427 (1991).
   PubMed Web of Science ®Google Scholar
• Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. Vaccine27(12), 1787–1796 (2009).
   PubMed Web of Science ®Google Scholar
• Kircheis R, Vondru P, Zinocker I et al. Immunization of Rhesus monkeys with the conjugate vaccine IGN402 induces an IgG immune response against carbohydrate and protein antigens, and cancer cells. Vaccine24(13), 2349–2357 (2006).
   PubMed Web of Science ®Google Scholar
• Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines6(5), 723–739 (2007).
   PubMed Web of Science ®Google Scholar
• Garcon N, Goldman M. Boosting vaccine power. Sci. Am.301(4), 72–79 (2009).
   PubMed Web of Science ®Google Scholar
• Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv. Exp. Med. Biol.667, 111–123 (2010).
   PubMed Web of Science ®Google Scholar
• Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature308(5958), 457–460 (1984).
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Baars M, van Amerongen G, van Beek R, Osterhaus AD. A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses. Vaccine20(1–2), 158–163 (2001).
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Claas EC, van Amerongen G, de Jong JC, Osterhaus AD. ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine17(11–12), 1355–1358 (1999).
   PubMed Web of Science ®Google Scholar
• Villacres-Eriksson M, Bergstrom-Mollaoglu M, Kaberg H, Lovgren K, Morein B. The induction of cell-associated and secreted IL-1 by iscoms, matrix or micelles in murine splenic cells. Clin. Exp. Immunol.93(1), 120–125 (1993).
   PubMed Web of Science ®Google Scholar
• Ozel M, Hoglund S, Gelderblom HR, Morein B. Quaternary structure of the immunostimulating complex (ISCOM). J. Ultrastruct. Mol. Struct. Res.102(3), 240–248 (1989).
   PubMedGoogle Scholar
• Lovgren K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand. J. Immunol.27(2), 241–245 (1988).
   PubMed Web of Science ®Google Scholar
• Jones LS, Cipolla D, Liu J, Shire SJ, Randolph TW. Investigation of protein–surfactant interactions by analytical ultracentrifugation and electron paramagnetic resonance: the use of recombinant human tissue factor as an example. Pharm. Res.16(6), 808–812 (1999).
   PubMed Web of Science ®Google Scholar
• Thaparr MA, Parr EL, Bozzola JJ, Parr MB. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM). Vaccine9(2), 129–133 (1991).
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Osterhaus A. Cytotoxic T-lymphocyte memory – role in cross-protective immunity against influenza. Vaccine13(8), 703–705 (1995).
   PubMed Web of Science ®Google Scholar
• Ronnberg B, Fekadu M, Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine13(14), 1375–1382 (1995).
   PubMed Web of Science ®Google Scholar
• Sundquist B, Lovgren K, Morein B. Influenza virus ISCOMs: antibody response in animals. Vaccine6(1), 49–53 (1988).
   PubMed Web of Science ®Google Scholar
• Brey RN. Development of vaccines based on formulations containing nonionic block copolymers. Pharm. Biotechnol.6, 297–311 (1995).
   PubMedGoogle Scholar
• Bennett B, Check IJ, Olsen MR, Hunter RL. A comparison of commercially available adjuvants for use in research. J. Immunol. Methods153(1–2), 31–40 (1992).
   PubMed Web of Science ®Google Scholar
• Howerton DA, Hunter RL, Ziegler HK, Check IJ. Induction of macrophage Ia expression in vivo by a synthetic block copolymer, L81. J. Immunol.144(5), 1578–1584 (1990).
   PubMed Web of Science ®Google Scholar
• Heath AW. Cytokines as immunological adjuvants. Pharm. Biotechnol.6, 645–658 (1995).
   PubMedGoogle Scholar
• Salgaller ML, Lodge PA. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J. Surg. Oncol.68(2), 122–138 (1998).
   PubMed Web of Science ®Google Scholar
• Pettit DK, Lawter JR, Huang WJ et al. Characterization of poly(glycolide-co-D,L-lactide)/poly(D,L-lactide) microspheres for controlled release of GM-CSF. Pharm. Res.14(10), 1422–1430 (1997).
   PubMed Web of Science ®Google Scholar
• Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res.60(14), 3832–3837 (2000).
   PubMed Web of Science ®Google Scholar
• Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med.11(4 Suppl.), S63–S68 (2005).
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Morris ML et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind Phase I/II study. J. Clin. Immunol.24(6), 693–701 (2004).
   PubMed Web of Science ®Google Scholar
• Mason KA, Ariga H, Neal R et al. Targeting Toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin. Cancer Res.11(1), 361–369 (2005).
   PubMed Web of Science ®Google Scholar
• Hengge UR, Cusini M. Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. Br. J. Dermatol.149(Suppl. 66), 15–19 (2003).
   PubMed Web of Science ®Google Scholar
• Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol.3(2), 196–200 (2002).
   PubMed Web of Science ®Google Scholar
• Asai Y, Ohyama Y, Gen K, Ogawa T. Bacterial fimbriae and their peptides activate human gingival epithelial cells through Toll-like receptor 2. Infect. Immun.69(12), 7387–7395 (2001).
   PubMed Web of Science ®Google Scholar
• Chernysh S, Kim SI, Bekker G et al. Antiviral and antitumor peptides from insects. Proc. Natl Acad. Sci. USA99(20), 12628–12632 (2002).
   PubMed Web of Science ®Google Scholar
• Allison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol. Methods95(2), 157–168 (1986).
   PubMed Web of Science ®Google Scholar
• Lindblad EB. Freund’s adjuvants. In: Vaccine Adjuvants: Preparation Methods and Research Protocols. O’Hagan DT (Ed.). Humana Press, NJ, USA, 49–63 (2000).
   Google Scholar
• Lindblad EB, Hau J. Escaping from the use of Freund’s complete adjuvant. In: Progress in the Reduction Refinement and Replacement of Animal Experimentation. Balls M, van Zeller A-M, Halder ME (Eds). Elsevier Science, Amsterdam, The Netherlands, 1681–1685 (2000).
   Google Scholar
• Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines2(2), 197–203 (2003).
   PubMedGoogle Scholar
• Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol.6, 277–296 (1995).
   PubMedGoogle Scholar
• Higgins DA, Carlson JR, Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine14(6), 478–484 (1996).
   PubMed Web of Science ®Google Scholar
• Tinsley-Bown AM, Fretwell R, Dowsett AB, Davis SL, Farrar GH. Formulation of poly(D,L-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery. J. Control. Release66(2–3), 229–241 (2000).
   PubMed Web of Science ®Google Scholar
• Heineman TC, Clements-Mann ML, Poland GA et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine17(22), 2769–2778 (1999).
   PubMed Web of Science ®Google Scholar
• De Donato S, Granoff D, Minutello M et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine17(23–24), 3094–3101 (1999).
   PubMed Web of Science ®Google Scholar
• Menegon T, Baldo V, Bonello C, Dalla CD, Di Tommaso A, Trivello R. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur. J. Epidemiol.15(6), 573–576 (1999).
   PubMed Web of Science ®Google Scholar
• Cunningham CK, Wara DW, Kang M et al. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin. Infect. Dis.32(5), 801–807 (2001).
   PubMed Web of Science ®Google Scholar
• AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J. Infect. Dis.183(4), 563–570 (2001).
   PubMed Web of Science ®Google Scholar
• Makidon PE, Bielinska AU, Nigavekar SS et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One3(8), e2954 (2008).
   PubMed Web of Science ®Google Scholar
• Hamouda T, Chepurnov A, Mank N et al. Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum. Vaccin. DOI: 10.4161/hv.6.7.11818 (2010) (Epub ahead of print).
   Google Scholar
• Bielinska AU, Chepurnov AA, Landers JJ et al. A novel, killed-virus nasal vaccinia virus vaccine. Clin. Vaccine Immunol.15(2), 348–358 (2008).
   PubMedGoogle Scholar
• Bielinska AU, Janczak KW, Landers JJ et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect. Immun.75(8), 4020–4029 (2007).
   PubMed Web of Science ®Google Scholar
• Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR Jr. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses24(2), 271–281 (2008).
   PubMed Web of Science ®Google Scholar
• Bielinska AU, Gerber M, Blanco LP et al. Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant. Crit. Rev. Immunol.30(2), 189–199 (2010).
   PubMed Web of Science ®Google Scholar
• Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit. Rev. Ther. Drug Carrier Syst.12(1), 1–99 (1995).
   PubMed Web of Science ®Google Scholar
• Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol.16 [published erratum appears in Nat. Biotechnol.16(5), 478 (1998)](2), 153–157 (1998).
   Google Scholar
• Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun.59(9), 2978–2986 (1991).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT. HIV and mucosal immunity. Lancet337(8752), 1289 (1991).
   PubMedGoogle Scholar
• Maloy KJ, Donachie AM, O’Hagan DT, Mowat AM. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology81(4), 661–667 (1994).
   PubMed Web of Science ®Google Scholar
• Moore A, McGuirk P, Adams S et al. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine13(18), 1741–1749 (1995).
   PubMed Web of Science ®Google Scholar
• Nixon DF, Hioe C, Chen PD et al. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine14(16), 1523–1530 (1996).
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials9(4), 356–362 (1988).
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers. J. Biomed. Mater. Res.22(10), 837–858 (1988).
   PubMed Web of Science ®Google Scholar
• Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity11(6), 753–761 (1999).
   PubMed Web of Science ®Google Scholar
• Lutsiak ME, Robinson DR, Coester C, Kwon GS, Samuel J. Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm. Res.19(10), 1480–1487 (2002).
   PubMed Web of Science ®Google Scholar
• Newman KD, Elamanchili P, Kwon GS, Samuel J. Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J. Biomed. Mater. Res.60(3), 480–486 (2002).
   PubMed Web of Science ®Google Scholar
• Jung T, Kamm W, Breitenbach A, Hungerer KD, Hundt E, Kissel T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide), evaluation of antibody response after oral and nasal application in mice. Pharm. Res.18(3), 352–360 (2001).
   PubMed Web of Science ®Google Scholar
• Seder RA, Gurunathan S. DNA vaccines – designer vaccines for the 21st Century. N. Engl. J. Med.341(4), 277–278 (1999).
   PubMed Web of Science ®Google Scholar
• Calarota S, Bratt G, Nordlund S et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet351(9112), 1320–1325 (1998).
   PubMed Web of Science ®Google Scholar
• Amara RR, Villinger F, Altman JD et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science292(5514), 69–74 (2001).
   PubMed Web of Science ®Google Scholar
• Schneider J, Gilbert SC, Blanchard TJ et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med.4(4), 397–402 (1998).
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature408(6812), 605–609 (2000).
   PubMed Web of Science ®Google Scholar
• Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat. Med.4, 365–368 (1998).
   PubMed Web of Science ®Google Scholar
• Ando S, Putnam D, Pack DW, Langer R. PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J. Pharm. Sci.88(1), 126–130 (1999).
   PubMed Web of Science ®Google Scholar
• Walter E, Moelling K, Pavlovic J, Merkle HP. Microencapsulation of DNA using poly(DL-lactide-co-glycolide), stability issues and release characteristics. J. Control. Release61(3), 361–374 (1999).
   PubMed Web of Science ®Google Scholar
• Otten GR, Schaefer M, Doe B et al. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J. Virol.79(13), 8189–8200 (2005).
   PubMed Web of Science ®Google Scholar
• Denis-Mize KS, Dupuis M, MacKichan ML et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther.7(24), 2105–2112 (2000).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Singh M, Kazzaz J et al. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine20(27–28), 3389–3398 (2002).
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres. J. Pharm. Pharmacol.39(9), 698–704 (1987).
   PubMed Web of Science ®Google Scholar
• Puri N, Sinko PJ. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation. J. Control. Release69(1), 69–80 (2000).
   PubMed Web of Science ®Google Scholar
• Cleland JL, Barron L, Daugherty A et al. Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120. J. Pharm. Sci.85(12), 1350–1357 (1997).
   Web of Science ®Google Scholar
• Singh M, Carlson JR, Briones M et al. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine16(19), 1822–1827 (1998).
   PubMed Web of Science ®Google Scholar
• Singh M, Li XM, McGee JP et al. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine15(5), 475–481 (1997).
   PubMed Web of Science ®Google Scholar
• Challacombe SJ, Rahman D, Jeffery H, Davis SS, O’Hagan DT. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology76(1), 164–168 (1992).
   PubMed Web of Science ®Google Scholar
• Challacombe SJ, Rahman D, O’Hagan DT. Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine15(2), 169–175 (1997).
   PubMed Web of Science ®Google Scholar
• Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer’s patches. J. Control. Release11, 205–214 (1990).
   Web of Science ®Google Scholar
• Conway MA, Madrigal-Estebas L, McClean S, Brayden DJ, Mills KH. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine19(15–16), 1940–1950 (2001).
   PubMed Web of Science ®Google Scholar
• Shahin R, Leef M, Eldridge J, Hudson M, Gilley R. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect. Immun.63(4), 1195–1200 (1995).
   PubMed Web of Science ®Google Scholar
• Whittum-Hudson JA, An LL, Saltzman WM, Prendergast RA, MacDonald AB. Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Nat. Med.2(10), 1116–1121 (1996).
   PubMed Web of Science ®Google Scholar
• Allaoui-Attarki K, Pecquet S, Fattal E et al. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect. Immun.65(3), 853–857 (1997).
   PubMed Web of Science ®Google Scholar
• Seo JY, Seong SY, Ahn BY, Kwon IC, Chung H, Jeong SY. Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin encapsulated in microspheres. Infect. Immun.70(3), 1143–1149 (2002).
   PubMed Web of Science ®Google Scholar
• Kende M, Yan C, Hewetson J, Frick MA, Rill WL, Tammariello R. Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge. Vaccine20(11–12), 1681–1691 (2002).
   PubMed Web of Science ®Google Scholar
• Marx PA, Compans RW, Gettie A et al. Protection against vaginal SIV transmission with microencapsulated vaccine. Science260(5112), 1323–1327 (1993).
   PubMed Web of Science ®Google Scholar
• Tseng J, Komisar JL, Trout RN et al. Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres. Infect. Immun.63(8), 2880–2885 (1995).
   PubMed Web of Science ®Google Scholar
• Mathiowitz E, Jacob JS, Jong YS et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature386(6623), 410–414 (1997).
   PubMed Web of Science ®Google Scholar
• Eyles JE, Spiers ID, Williamson ED, Alpar HO. Tissue distribution of radioactivity following intranasal administration of radioactive microspheres. J. Pharm. Pharmacol.53(5), 601–607 (2001).
   PubMed Web of Science ®Google Scholar
• Lambert JS, Keefer M, Mulligan MJ et al. A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine19(23–24), 3033–3042 (2001).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol.108(3), 241–247 (2003).
   PubMed Web of Science ®Google Scholar
• Brayden DJ. Oral vaccination in man using antigens in particles: current status. Eur. J. Pharm. Sci.14(3), 183–189 (2001).
   PubMed Web of Science ®Google Scholar
• Butts C, Murray N, Maksymiuk A et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol.23(27), 6674–6681 (2005).
   PubMed Web of Science ®Google Scholar
• North S, Butts C. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev. Vaccines4(3), 249–257 (2005).
   PubMed Web of Science ®Google Scholar
• Sangha R, North S. L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. Expert Opin. Biol. Ther.7(11), 1723–1730 (2007).
   PubMed Web of Science ®Google Scholar
• Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature252(5480), 252 (1974).
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, Putman D, Louis L, Neerunjun D. Comparative effect and fate of non-entrapped and liposome-entrapped neuraminidase injected into rats. Biochem. J.140(2), 323–330 (1974).
   PubMed Web of Science ®Google Scholar
• Alving CR. Liposomes as carriers of antigens and adjuvants. J. Immunol. Methods140(1), 1–13 (1991).
   PubMed Web of Science ®Google Scholar
• Alving CR. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology187(3–5), 430–446 (1993).
   PubMed Web of Science ®Google Scholar
• van Rooijen N, van Nieuwmegen R. Liposomes in immunology: evidence that their adjuvant effect results from surface exposition of the antigens. Cell. Immunol.49(2), 402–407 (1980).
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Liposomes, a tale of drug targeting. J. Drug Target1(1), 3–6 (1993).
   PubMed Web of Science ®Google Scholar
• Reddy R, Zhou F, Huang L, Carbone F, Bevan M, Rouse BT. pH sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein. J. Immunol. Methods141(2), 157–163 (1991).
   PubMed Web of Science ®Google Scholar
• Hedlund G, Jansson B, Sjogren HO. Comparison of immune responses induced by rat RT-1 antigens presented as inserts into liposomes, as protein micelles and as intact cells. Immunology53(1), 69–78 (1984).
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, Davis D, Davies A. Liposomes as immunological adjuvants: antigen incorporation studies. Vaccine5(2), 145–151 (1987).
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Liposomes as a drug delivery system: optimization studies. Adv. Exp. Med. Biol.238, 151–159 (1988).
   PubMedGoogle Scholar
• Davis D, Davies A, Gregoriadis G. Liposomes as adjuvants with immunopurified tetanus toxoid: the immune response. Immunol. Lett.14(4), 341–348 (1987).
   PubMed Web of Science ®Google Scholar
• Antimisiaris SG, Jayasekera P, Gregoriadis G. Liposomes as vaccine carriers. Incorporation of soluble and particulate antigens in giant vesicles. J. Immunol. Methods166(2), 271–280 (1993).
   PubMed Web of Science ®Google Scholar
• Altin JG, Parish CR. Liposomal vaccines – targeting the delivery of antigen. Methods40(1), 39–52 (2006).
   PubMed Web of Science ®Google Scholar
• Felnerova D, Viret JF, Gluck R et al. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol.15, 518–529 (2004).
   PubMed Web of Science ®Google Scholar
• Sato Y, Murase K, Kato J et al. Resolution of rat liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen specific chaperon. Nat. Biotechnol.26, 431–442 (2008).
   PubMed Web of Science ®Google Scholar
• Gluck R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ Jr. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J. Clin. Invest.90(6), 2491–2495 (1992).
   PubMed Web of Science ®Google Scholar
• Gluck R, Metcalfe IC. New technology platforms in the development of vaccines for the future. Vaccine20(Suppl. 5), B10–B16 (2002).
   PubMed Web of Science ®Google Scholar
• Gluck R. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine17(13–14), 1782–1787 (1999).
   PubMed Web of Science ®Google Scholar
• Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine20(Suppl. 5), B17–B23 (2002).
   PubMed Web of Science ®Google Scholar
• Alving CR. Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity. Ann NY Acad. Sci.754, 143–152 (1995).
   PubMed Web of Science ®Google Scholar
• Gluck R, Metcalfe IC. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems. Vaccine21(7–8), 611–615 (2003).
   PubMed Web of Science ®Google Scholar
• Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem.56, 365–394 (1987).
   PubMed Web of Science ®Google Scholar
• Jackson DC, Crabb BS, Poumbourios P, Tulip WR, Laver WG. Three antibody molecules can bind simultaneously to each monomer of the tetramer of influenza virus neuraminidase and the trimer of influenza virus hemagglutinin. Arch. Virol.116(1–4), 45–56 (1991).
   PubMed Web of Science ®Google Scholar
• Lowell GH, Smith LF, Seid RC, Zollinger WD. Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants. J. Exp. Med.167(2), 658–663 (1988).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Palin KJ, Davis SS. Poly(butyl-2-cyanoacrylate) particles as adjuvants for oral immunization. Vaccine7(3), 213–216 (1989).
   PubMed Web of Science ®Google Scholar
• Freund J. The mode of action of immunologic adjuvants. Bibl. Tuberc.10, 130–148 (1956).
   Google Scholar
• Gluck R, Burri KG, Metcalfe I. Adjuvant and antigen delivery properties of virosomes. Curr. Drug Deliv.2(4), 395–400 (2005).
   PubMedGoogle Scholar
• Gluck R, Moser C, Metcalfe IC. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opin. Biol. Ther.4(7), 1139–1145 (2004).
   PubMed Web of Science ®Google Scholar
• Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods40(1), 60–65 (2006).
   PubMed Web of Science ®Google Scholar
• Huckriede A, Bungener L, Stegmann T et al. The virosome concept for influenza vaccines. Vaccine23(Suppl. 1), S26–S38 (2005).
   PubMed Web of Science ®Google Scholar
• Shouval D, Ilan Y, Adler R et al. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine12(15), 1453–1459 (1994).
   PubMed Web of Science ®Google Scholar
• Yap I, Guan R, Chan SH. Recombinant DNA hepatitis B vaccine containing pre-S components of the coat protein – a preliminary study on immunogenicity. Vaccine10(7), 439–442 (1992).
   PubMed Web of Science ®Google Scholar
• Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J. Virol.72(2), 1345–1353 (1998).
   PubMed Web of Science ®Google Scholar
• Nardin EH, Oliveira GA, Calvo-Calle JM et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun.72(11), 6519–6527 (2004).
   PubMed Web of Science ®Google Scholar
• Oliveira GA, Wetzel K, Calvo-Calle JM et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a Phase I trial. Infect. Immun.73(6), 3587–3597 (2005).
   PubMed Web of Science ®Google Scholar
• Gupta RK, Rost BE, Relyveld E, Siber GR. Adjuvant properties of aluminum and calcium compounds. Pharm. Biotechnol.6, 229–248 (1995).
   PubMedGoogle Scholar
• Volkin D, Middaugh C. Stability of Protein Pharmaceuticals Part A – Chemical and Physical Pathways of Protein Degradation. Plenum Press, NY, USA (1992).
   Google Scholar
• Arakawa T, Timasheff SN. The stabilization of proteins by osmolytes. Biophys. J.47(3), 411–414 (1985).
   PubMed Web of Science ®Google Scholar
• Middaugh CR. Advances in the delivery of pharmaceuticals. J. Pharm. Sci.87(11), 1265–1266 (1998).
   PubMed Web of Science ®Google Scholar
• Middaugh CR, Edwards KL. Recent advances in our understanding of protein conformational stability from a pharmaceutical perspective. Expert Opin. Investig. Drugs7(9), 1493–1500 (1998).
   PubMedGoogle Scholar
• Klencke B, Matijevic M, Urban RG et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin. Cancer Res.8(5), 1028–1037 (2002).
   PubMed Web of Science ®Google Scholar
• Toda S, Ishii N, Okada E et al. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-γ antibody. Immunology92(1), 111–117 (1997).
   PubMed Web of Science ®Google Scholar
• Giannasca PJ, Boden JA, Monath TP. Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins. Infect. Immun.65(10), 4288–4298 (1997).
   PubMed Web of Science ®Google Scholar
• Foster N, Clark MA, Jepson MA, Hirst BH. Ulex europaeus 1 lectin targets microspheres to mouse Peyer’s patch M-cells in vivo. Vaccine16(5), 536–541 (1998).
   PubMed Web of Science ®Google Scholar
• Hussain N, Jani PU, Florence AT. Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm. Res.14(5), 613–618 (1997).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Schleiss MR, Berencsi K et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J. Infect. Dis.185(5), 686–690 (2002).
   PubMed Web of Science ®Google Scholar
• Agren L, Sverremark E, Ekman L et al. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects. J. Immunol.164(12), 6276–6286 (2000).
   PubMed Web of Science ®Google Scholar
• Agren LC, Ekman L, Lowenadler B, Lycke NY. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol.158(8), 3936–3946 (1997).
   PubMed Web of Science ®Google Scholar
• Agren LC, Ekman L, Lowenadler B, Nedrud JG, Lycke NY. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol.162(4), 2432–2440 (1999).
   PubMed Web of Science ®Google Scholar
• Goletz TJ, Klimpel KR, Arora N, Leppla SH, Keith JM, Berzofsky JA. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Proc. Natl Acad. Sci. USA94(22), 12059–12064 (1997).
   PubMed Web of Science ®Google Scholar
• Davis MM, Butchart AT, Coleman MS et al. The expanding vaccine development pipeline, 1995–2008. Vaccine28(5), 1353–1356 (2010).
   PubMed Web of Science ®Google Scholar
• Voss G, Manson K, Montefiori D et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J. Virol.77(2), 1049–1058 (2003).
   PubMed Web of Science ®Google Scholar
• Casimiro DR, Chen L, Fu TM et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol.77(11), 6305–6313 (2003).
   PubMed Web of Science ®Google Scholar
• Vajdy M SM, Medina-Selby A, Coit D et al. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J. Gen. Virol.87, 2253–2262 (2006).
   PubMed Web of Science ®Google Scholar
• Barnett SW, Rajasekar S, Legg H et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine15(8), 869–873 (1997).
   PubMed Web of Science ®Google Scholar
• Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J. Infect. Dis.174(6), 1168–1175 (1996).
   PubMed Web of Science ®Google Scholar
• Peng B, Voltan R, Cristillo AD et al. Replicating Ad-recombinants encoding non-myristoylated rather than wild-type HIV Nef elicit enhanced cellular immunity. AIDS20(17), 2149–2157 (2006).
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Hilbert AK, Bugarini R et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine24(16), 3063–3065 (2006).
   PubMed Web of Science ®Google Scholar
• Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine25(20), 3955–3961 (2007).
   PubMed Web of Science ®Google Scholar
• Nitayaphan S, Khamboonruang C, Sirisophana N et al. A Phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. Vaccine18(15), 1448–1455 (2000).
   PubMed Web of Science ®Google Scholar
• Keeney RT, Edelman R. Survey of human-use adjuvants. Expert Rev. Vaccines2, 167–188 (2003).
   PubMedGoogle Scholar
• Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines2, 197–203 (2003).
   PubMedGoogle Scholar
• Mengiardi B, Berger R, Just M et al. Virosomes as carriers for combined vaccines. Vaccines13, 1306–1315 (1995).
   PubMed Web of Science ®Google Scholar
• Poltl-Frank F, Zubriggen R, Helg A et al. Use of reonstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide based vaccine. Clin. Exp. Immunol.117, 496–503 (1999).
   PubMed Web of Science ®Google Scholar
• Hunziker IP, Zubriggen R, Gluck R et al. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol. Immunol.38, 475–484 (2001).
   PubMed Web of Science ®Google Scholar
• Cusi MG, Zubriggen R, Correale P et al. Influenza virosomes are an efficient delivery system for respiratory syncytial virus–F antigen inducing humoral and cell-mediated immunity. Vaccine20, 3436–3442 (2002).
   PubMed Web of Science ®Google Scholar
• Cusi MG, Zubriggen R, Valassina M et al. Intranasal immunization with Mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. Virology277, 111–118 (2000).
   PubMed Web of Science ®Google Scholar